GlassScriptPhysician profile
Rija Amir
NPI 1639743834
$6,839.15
in general payments reported to CMS, 2019-2025
23 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $725 · 2022: $1,578 · 2023: $2,202 · 2024: $2,038 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,522 · Education: $14.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,521.68 |
| Education | $14.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,664.16 | 2021-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $806.01 | 2021-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $735.51 | 2021-2025 | Lupkynis |
| Abbvie INC. | $521.18 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $518.66 | 2023-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $428.45 | 2021-2023 | Saphnelo |
| Glaxosmithkline, LLC. | $378.79 | 2023-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $333.01 | 2021-2024 | |
| Organon LLC | $252.52 | 2021-2024 | Hadlima, Renflexis |
| Janssen Biotech, INC. | $223.85 | 2021-2024 | Tremfya |
| Pfizer INC. | $211.86 | 2023-2025 | |
| Radius Health, INC. | $137.18 | 2024 | Tymlos |
| Tersera Therapeutics LLC | $121.41 | 2022-2024 | Quzyttir |
| Lilly USA, LLC | $107.95 | 2022-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $84.62 | 2023 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $65.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $65.54 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.34 | 2023 | Cyltezo |
| Genentech USA, INC. | $39.41 | 2024 | Actemra |
| Fresenius Kabi USA, LLC | $34.51 | 2023-2024 | Idacio |
| Genzyme Corporation | $25.44 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $21.22 | 2023 | Opsumit |
| Sandoz INC. | $20.92 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rija Amir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.